

April 18, 2006

To Whom It May Concern

Company: Taisho Pharmaceutical Co., Ltd.  
Representative: Akira Uehara, President  
(First Section of TSE: Code 4535)  
Contact: Makoto Funahashi, General Manager  
Public Relations Section  
(Tel: +81-3-3985-1115)

## Taisho Announces Share Purchase

At a meeting of the Board of Directors today, Taisho Pharmaceutical Co., Ltd. (Taisho; President: Akira Uehara) resolved to purchase shares of Yomeishu Seizo Co., Ltd. (Yomeishu Seizo). Details are as follows.

### 1. Rationale for Share Purchase

Aiming for further growth in the self-medication and related markets, Taisho and Yomeishu Seizo announced a business and capital tie-up on July 11, 2005. Since then, the two companies have taken steps to strengthen their partnership, building even closer links to take their businesses forward. The share purchase announced today is a part of this effort.

### 2. Number of Shares to be Purchased

Taisho will purchase 1,805,000 shares of Yomeishu Seizo's common stock through the ToSTNeT-1 after-hours market of the Tokyo Stock Exchange.

### 3. Holding Before and After Purchase

Before purchase: 4,795,000 shares (Taisho's equity interest: 14.5%)  
After purchase: 6,600,000 shares (Taisho's equity interest: 20.0%)

### 4. Purchase Schedule

April 18, 2006: After-hours market of the Tokyo Stock Exchange (ToSTNeT-1)

### 5. Impact on Earnings

This purchase will increase Taisho's holding to 20.0%, thereby making Yomeishu Seizo an equity-method affiliate.